Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

136 results
Display

Performance Evaluation of Aptima HBV and HCV Quant Assays in the Panther System

Choi YJ, Kim B, Kim Y, Lee KA

Background: Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections remain a serious health problem despite advancements in their prevention and treatment. Guidelines on their management recommend using viral...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of HCV Genotype with Low Titer of HCV RNA Using the Methods of Concentration

Kang J, Kang Jw, Ko DH, Youn M, Kwon SY

Analysis of HCV genotypes can help identify infection routes and the development of treatment methods. However, in some samples with a low titer of HCV RNA, it is difficult to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Huang CF, Wu PF, Yeh ML, Huang CI, Liang PC, Hsu CT, Hsu PY, Liu HY, Huang YC, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Yu ML

Background/Aims: Obstacles exist in facilitating hepatitis C virus (HCV) care cascade. To increase timely and accurate diagnosis, disease awareness and accessibility, in-hospital HCV reflex testing followed by automatic appointments and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Characterization and applications of chimeric mice with humanized livers for preclinical drug development

Tateno C, Kojima Y

We have succeeded in stable mass production of chimeric PXB-mice, whose liver is repopulated by human hepatocytes at a ratio of more than 70%, and we are providing these mice...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Analysis of HCV RNA Genotypes and Quantitative Values of Korean HCV NAT Reactive Blood Donors

Shin S, Kang JW, Kang J, Seo YI, Park JR, Lee DD, Min H, Kim M

BACKGROUND: Ever since the Korean Red Cross adopted HCV NAT for blood donor screening in 2005, HCV NAT reactive donors have been identified every year. The identification of the clinical...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure

Parigi TL, Torres MC, Aghemo A

Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Investigation of the Association of HCV or HIV Markers in Non-Discriminated Blood Donations

Kang J, Shin S, Kang JW, Seo YI, Min H, Kim M

HBV core antibody and surface antibody test are currently conducted for those donors showing non-discriminated reactive (NDR) results on a nucleic acid amplification test (NAT) as a blood donor screening...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Estimation of the Residual Risk of Transfusion-Transmissible Infectious Agents in Korea

Kang JW, Shin S, Seo DH, Kang J, Ko DH, Song CE, Lee MN, Kim JN

BACKGROUND: The risk of transfusion-transmissible infections (TTIs) of HBV, HCV, and HIV in Korea has been reduced significantly by strengthening the blood safety policies. On the other hand, the risk...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?

Huang CF, Yu ML

During the clinical trial development of directly acting antivirals (DAAs), evidence regarding the treatment efficacy in chronic hepatitis C patients with hepatocellular carcinoma (HCC) was scarce because these patients have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Development of a Rapid Automated Fluorescent Lateral Flow Immunoassay to Detect Hepatitis B Surface Antigen (HBsAg), Antibody to HBsAg, and Antibody to Hepatitis C

Ryu JH, Kwon M, Moon JD, Hwang MW, Lee JM, Park KH, Yun SJ, Bae HJ, Choi A, Lee H, Jung B, Jeong J, Han K, Kim Y, Oh EJ

BACKGROUND: Accurate, rapid, and cost-effective screening tests for hepatitis B virus (HBV) and hepatitis C virus (HCV) infection may be useful in laboratories that cannot afford automated chemiluminescent immunoassays (CLIAs)....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Real-World Clinical Efficacy and Tolerability of Direct-Acting Antivirals in Hepatitis C Monoinfection Compared to Hepatitis C/Human Immunodeficiency Virus Coinfection in a Community Care Setting

Gayam V, Hossain MR, Khalid M, Chakaraborty S, Mukhtar O, Dahal S, Mandal AK, Gill A, Garlapati , Ramakrishnaiah S, Mowyad K, Sherigar J, Mansour M, Mohanty S

BACKGROUND/AIMS: Limited data exist comparing the safety and efficacy of direct-acting antivirals (DAAs) in hepatitis C virus (HCV) monoinfected and HCV/human immunodeficiency virus (HIV) coinfected patients in the real-world clinic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Long-Term Stability of HBV, HCV, and HIV-1 National Reference Standards for in vitro Diagnostic Medical Devices Intended to Be Used for the Nucleic Acid Amplification Test

Choi KY, Youn KW, Cha YJ, Min HK, Kim J

BACKGROUND: National reference standards are essential to the quality assessment and regulatory approval of in vitro diagnostic medical devices. However, the long-term stability of national reference standards has not been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
PD-L1 Expression on Circulating CD34+ Hematopoietic Stem Cells Closely Correlated with T-cell Apoptosis in Chronic Hepatitis C Infected Patients

Abdellatif H, Shiha G

BACKGROUND AND OBJECTIVES: Lack of understanding of the interplay between hematopoietic stem cells (HSCs) and the immune system has severely hampered stem cell research. Programmed death-1 (PD-L1) has been reported...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Consideration of Appropriateness of Application of Immunoblot Assay as a Reentry Test for HCV or HIV Screening Reactive Donors

Kang JW, Youn KW, Seo JH, Seo YI, Park S

BACKGROUND: Currently, serological assay, immunoblotting, and nucleic acid amplification test (NAT) are required as reentry tests for deferred donors with hepatitis C virus (HCV) or human immunodeficiency virus (HIV) screening...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Results of Proficiency Tests for HBsAg and Anti-HCV as the Blood Donor Screening Testing (2012~2015)

Lee MN, Kim JN, Cha YJ, Park QE, Kim HO, Kwon GC, Choi YS, Kwon JR

BACKGROUND: Donor screening test is one of the most important processes for blood safety management. Korea Center for Disease Control and Prevention (KCDC) has been conducting an annual proficiency test...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Utility of a New Automated Hepatitis C Virus Core Antigen Assay for Prediction of Treatment Response in Patients with Chronic Hepatitis C

Kim MN, Kim HS, Kim JK, Kim BK, Kim SU, Park JY, Kim DY, Ahn SH, Han KH

Hepatitis C virus core antigen (HCV Ag) is a recently developed marker of hepatitis C virus (HCV) infection. We investigated the clinical utility of the new HCV Ag assay for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New direct-acting antivirals for the treatment of chronic hepatitis C

Jeong SH

The successful development of direct-acting antivirals (DAA) represents a breakthrough in the treatment of hepatitis C virus (HCV) infection. Pegylated interferon alpha and ribavirin combination therapy for 24-48 weeks was...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Autologous Stem Cells Transplantation in Egyptian Patients with Liver Cirrhosis on Top of Hepatitis C Virus

Al Tayeb H, El Dorry A, Amer N, Mowafy N, Zimaity M, Bayoumy E, Saleh SA

BACKGROUND AND OBJECTIVES: Use of pluripotent stem cells is an ideal solution for liver insufficiencies. This work aims is to evaluate the safety and feasibility of autologous stem cells transplantation...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Application of a Grey Zone for HCV and HIV Immunoassays for Blood Donor Screening: Is It still Necessary?

Cho YJ, Kwon SY, Yang JH, Kim J, Kim BH, Shin S

BACKGROUND: When enzyme immunoassays (EIA) were implemented, considering the limited sensitivity of 1st generation EIAs, the Korean Red Cross (KRC) applied grey zones for detection of weak reactive samples that...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Residual Risk of Transfusion-Transmitted Infection with Hepatitis C Virus since the Introduction of Nucleic Acid Testing in Korea

Oh D, Choi G, Min H, Kang J

BACKGROUND: In 2005, the Korean Red cross introduced mini-pool nucleic acid testing (NAT) for human immunodeficiency virus (HIV) and hepatitis C virus (HCV), which upgraded to individual donation (ID) NAT...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr